Tocilizumab, netakimab, and baricitinib in patients with mild-to-moderate COVID-19: An observational study

OBJECTIVE: The aim of the study was to assess inflammatory markers and clinical outcomes in adult patients admitted to hospital with mild-to-moderate COVID-19 and treated with a combination of standard-of-care (SOC) and targeted immunosuppressive therapy including anti-IL-17A (netakimab), anti-IL-6R...

Descripción completa

Detalles Bibliográficos
Autores principales: Bryushkova, Ekaterina A., Skatova, Valeria D., Mutovina, Zinaida Y., Zagrebneva, Alena I., Fomina, Daria S., Kruglova, Tatyana S., Akopyan, Anna A., Strazhesko, Irina D., Lukyanov, Sergey A., Tkacheva, Olga N., Lysenko, Maryana A., Chudakov, Dmitry M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9401152/
https://www.ncbi.nlm.nih.gov/pubmed/36001576
http://dx.doi.org/10.1371/journal.pone.0273340

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9401152/
https://www.ncbi.nlm.nih.gov/pubmed/36001576
http://dx.doi.org/10.1371/journal.pone.0273340

Ejemplares similares